EVLO News and Press, Evelo Biosciences Inc. From 03/26/22

CAMBRIDGE, Mass., March 26, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today presented a late-breaking oral abstract on ...

Image source: The Motley Fool. Evelo Biosciences, Inc. (NASDAQ: EVLO) Q4 2021 Earnings Call Mar 24, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Evelo Biosciences, Inc. (EVLO) Q4 2021 Earnings Call Transcript

Clinical-stage biotech, Evelo Biosciences (EVLO +17.7%), is trading higher Thursday after reporting its third consecutive quarterly earnings beat with its financials for 4Q 2021. Net loss for the quarter contracted ~1% YoY to $28.7 million as R&D expenses declined ~15% YoY to $18.9M....

Evelo Biosciences, Inc. (EVLO) Q4 2021 Earnings Conference Call March 24, 2022 8:30 AM ET Company Participants Kendra Sweeney - Investor Relations Simba Gill - Chief Executive Officer Mark Bodmer - President of R&D, Chief Scientific Officer Jonathan Zung - Chief Development Officer Confer...

Evelo Biosciences press release (NASDAQ:EVLO): Q4 GAAP EPS of -$0.54 beats by $0.08. As of December 31, 2021, cash and cash equivalents were $68.4 million, as compared to cash and cash equivalents of $68.9 million as of December 31, 2020. For further details see: Evelo Biosciences GAAP ...

–Oral presentation on EDP1815 Phase 2 data in psoriasis accepted in late-breaking abstract session at AAD on Saturday, March 26, 2022 – –Positive data reported on faster release capsule– –Phase 2 data from EDP1815 in atopic dermatitis on-track for 1H 2...

If you’re looking for the most exciting way to make money in the stock market today, penny stocks should be at the top of your list. These high-flying, low-priced names have become a mainstay for day traders and investors alike. The idea of “getting in early” tends to a...

CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference ca...

CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a virtual event...

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that Simba Gill, Ph.D., Chief Exe...